Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.
In this update of our 2005 document, we used an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents for the prevention of emesis and nausea following anticancer chemotherapies of high emetic risk. A three-drug combination of a 5-hydroxytryptamine type 3 receptor (5-HT(3)) receptor antagonist, dexamethasone, and aprepitant beginning before chemotherapy and continuing for up to 4 days remains the standard of care. We address issues of dose, schedule, and route of administration of five selective 5-HT(3) receptor antagonists. We conclude that, for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. In trials designed to prove the equivalence of palonosetron to ondansetron and granisetron, palonosetron proved superior in emesis prevention, while adverse effects were comparable. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration.
Kris
Mark G
MG
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. krism@mskcc.org
Tonato
Maurizio
M
Bria
Emilio
E
Ballatori
Enzo
E
Espersen
Birgitte
B
Herrstedt
Jørn
J
Rittenberg
Cynthia
C
Einhorn
Lawrence H
LH
Grunberg
Steven
S
Saito
Mitsue
M
Morrow
Gary
G
Hesketh
Paul
P
D000932:Antiemetics / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D006801:Humans; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control*; D064729:Neurokinin-1 Receptor Antagonists; D012702:Serotonin Antagonists / Q000008:administration & dosage; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D064729:Neurokinin-1 Receptor Antagonists; D012702:Serotonin Antagonists; D003907:Dexamethasone
Cancer. 2003 May 1;97(9):2290-300
12712486
Support Care Cancer. 2005 Feb;13(2):85-96
15565277
Clin Ther. 2003 May;25(5):1407-19
12867217
N Engl J Med. 2008 Jun 5;358(23):2482-94
18525044
J Clin Oncol. 1985 Oct;3(10):1379-84
4045527
J Natl Cancer Inst. 1991 May 1;83(9):613-20
1850806
J Clin Oncol. 1989 Jun;7(6):700-5
2523957
Semin Oncol. 1995 Aug;22(4 Suppl 10):24-30
7570051
Anticancer Drugs. 1995 Feb;6 Suppl 1:15-21
7749165
N Engl J Med. 1999 Jan 21;340(3):190-5
9917226
Eur J Cancer. 1990;26 Suppl 1:S33-6
2169784
J Clin Oncol. 1992 Dec;10(12):1969-75
1453211
Ann Oncol. 1998 Aug;9(8):811-9
9789602
Crit Rev Oncol Hematol. 2007 Feb;61(2):162-75
17208005
Support Care Cancer. 1996 Mar;4(2):141-6
8673351
Eur J Cancer. 2001 Dec;37(18):2398-404
11720834
Cancer. 1985 Feb 1;55(3):527-34
3880660
N Engl J Med. 1990 Mar 22;322(12):816-21
2137902
Lancet Oncol. 2009 Feb;10(2):115-24
19135415
J Clin Oncol. 1995 Sep;13(9):2417-26
7666102
Med Clin North Am. 1987 Mar;71(2):289-301
3546981
Ann Oncol. 2004 Feb;15(2):330-7
14760130
Eur J Cancer. 2001 May;37(7):835-42
11313170
Cancer. 1996 Nov 15;78(10):2193-8
8918414
Eur J Cancer. 2003 May;39(8):1074-80
12736106
Ann Oncol. 2006 Sep;17(9):1441-9
16766588
Ann Oncol. 2003 Oct;14(10):1570-7
14504060
Ann Oncol. 1998 Jun;9(6):661-6
9681082
Support Care Cancer. 1994 May;2(3):177-83
8032704
J Clin Oncol. 1998 Sep;16(9):2937-42
9738561
Cancer. 2003 Jun 15;97(12):3090-8
12784346
Br J Cancer. 1992 Jul;66(1):192-7
1386245
J Clin Oncol. 2000 Oct 1;18(19):3409-22
11013282
Oncology. 1994 Jan-Feb;51(1):113-8
8265095
J Clin Oncol. 1989 Aug;7(8):1137-41
2526864
J Clin Oncol. 1995 Apr;13(4):1036-43
7707101
J Clin Oncol. 1995 Sep;13(9):2408-16
7666101
Ann Intern Med. 1990 Dec 1;113(11):834-40
2146911
Cancer. 2002 Jun 1;94(11):3032-41
12115394
J Clin Oncol. 1998 Mar;16(3):1174-8
9508205
Support Care Cancer. 1994 Sep;2(5):297-300
8000726
Br J Cancer. 1994 May;69(5):967-71
8180032
J Clin Oncol. 1999 Jan;17(1):338-43
10458252
Oncology. 1992;49(4):295-304
1387929
J Clin Oncol. 1994 May;12(5):1045-9
8164028
Support Care Cancer. 1996 Nov;4(6):416-9
8961471
Cancer. 2003 Dec 1;98(11):2473-82
14635083
J Clin Oncol. 1991 May;9(5):721-8
1826739
J Clin Oncol. 1995 May;13(5):1242-8
7738628
Neuropharmacology. 1994 Feb;33(2):259-60
8035913
J Clin Pharmacol. 2007 Jul;47(7):834-40
17525168